Prosecution Insights
Last updated: April 19, 2026
Application No. 17/802,896

MAP KINASE KINASE (MKK7) INHIBITORS AND USES THEREOF

Final Rejection §112
Filed
Aug 26, 2022
Examiner
HIRAKIS, SOPHIA P
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
DANA-FARBER CANCER INSTITUTE, INC.
OA Round
2 (Final)
50%
Grant Probability
Moderate
3-4
OA Rounds
3y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allow Rate
13 granted / 26 resolved
-10.0% vs TC avg
Strong +65% interview lift
Without
With
+65.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
52 currently pending
Career history
78
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
32.6%
-7.4% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
33.1%
-6.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 26 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application, filed 08/26/2022, is a national stage entry of PCT/US2021/019602, filed 02/25/2021, which claims domestic priority to U.S. provisional application 62/983,330, filed 02/28/2020. Amendments and Claim Status The following amendment filed on 12/18/2026 is acknowledged and entered. Claims 1, 9, 23, 24, 36, 38, 45, 47, 51-54, 56, 58, 68, 70, 71, 73, and 75 are amended; Claims 2-8, 10-22, 25-35, 37, 39-44, 46, 48-50, 55, 57, 59-67, 69, 72, 74 and 76-82 are cancelled; Claims 1, 9, 23, 24, 36, 38, 45, 47, 51-54, 56, 58, 68, 70, 71, 73, and 75 are pending; Claims 58, 68, 70, 71, 73, and 75 remain withdrawn according to 37 CFR § 1.142(b), as being drawn to a non-elected invention and species; Claims 1, 9, 23, 24, 36, 38, 45, 47, 51-54, and 56 read on an elected species and invention and are examined on the merits as such. Information Disclosure Statement An Information Disclosure Statement has not been submitted. Response to arguments Applicant’s arguments filed 12/18/2025 with respect to the claim objections and claim rejections under 35 U.S.C. §§ 112(a) and 103 have been fully considered. With respect to the objection to claims 51-54, claim amendments are insufficient to overcome the objection. As such, the objection is maintained. With respect to the rejection of claims 1, 2, 8, 9, 23-25, 36, 38, 45, 47 and 82 under 35 U.S.C. § 112 (a) as failing to comply with the written description requirement, the cancellation of claims 2, 8, 25, and 82 are sufficient to render the rejection against said claims moot. Furthermore, the amendment to independent claim 1 is sufficient to overcome the rejection. As such, the rejection is hereby withdrawn. With respect to the rejection of claims 1, 56, 57, and 82 under 35 U.S.C. § 103 as being unpatentable over Cumming et al. (WO 2001027089 A1, published April 19, 2001, cited in applicant IDS dated 11/23/2022), hereinafter Cumming in view of Patani et al., (Chem Rev (1996) 96, pg. 3147-3176, published December 19, 1996), hereinafter Patani, the cancellation of claims 57 and 82 are sufficient to render the rejection against said claims moot. Furthermore, the amendment to independent claim 1 is sufficient to overcome the rejection. As such, the rejection is hereby withdrawn. With respect to the amendment of claim 1, Applicant has stricken the definition of m and n from the claim and from the claim set altogether, which has rendered the claim indefinite. A new rejection under 35 U.S.C. § 112(b) is included hereinafter. Claim Objections Claims 51-54 are objected to for depending on a rejected claim (claim 1). Claim Rejections - 35 U.S.C. § 112 The following is a quotation of 35 U.S.C. § 112 (b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. § 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 9, 23, 24, 36, 38, 45, 47, and 56 are rejected under 35 U.S.C. § 112(b) or 35 U.S.C. § 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. § 112, the applicant), regards as the invention. Claim 1 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being incomplete for omitting essential elements, such omission amounting to a gap between the elements. See MPEP § 2172.01. The omitted elements are: m and n, which define the number of substituents of R2 and R3, respectively. Regarding claims 9, 23, 24, 36, 38, 45, 47, and 56, the claims depend on a claim rejected as being indefinite (claim 1) and fail to remedy the indefiniteness of the claim on which it depends, and is therefore dually rejected as indefinite. Conclusion No claims are allowed. Applicant's amendment necessitated the new grounds of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR § 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR § 1.17(a)) pursuant to 37 CFR § 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sophia P. Hirakis whose telephone number is +1 (571) 272-0118. The examiner can normally be reached within the hours of 5:00 am to 5:00pm EST, Monday through Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam C. Milligan can be reached on +1 (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is +1 (571) 273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call +1 (800) 786-9199 (IN USA OR CANADA) or +1 (571) 272-1000. /SOPHIA P HIRAKIS/Examiner, Art Unit 1623 /KARA R. MCMILLIAN/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Aug 26, 2022
Application Filed
Sep 16, 2025
Non-Final Rejection — §112
Dec 18, 2025
Response Filed
Mar 02, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12522616
THIAZOLOLACTAM COMPOUND AS ERK INHIBITOR AND USE THEREOF
2y 5m to grant Granted Jan 13, 2026
Patent 12486270
RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER
2y 5m to grant Granted Dec 02, 2025
Patent 12448365
ARYL AMINOPYRIMIDINES AS DUAL MERTK AND TYRO3 INHIBITORS AND METHODS THEREOF
2y 5m to grant Granted Oct 21, 2025
Patent 12383518
DISULFIDE-MASKED PRO-CHELATOR COMPOSITIONS AND METHODS OF USE
2y 5m to grant Granted Aug 12, 2025
Patent 12378203
NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF
2y 5m to grant Granted Aug 05, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
50%
Grant Probability
99%
With Interview (+65.0%)
3y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 26 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month